Jul 14, 2026 06:57AM
Jul 13, 2026 09:05AM
Jul 13, 2026 09:05AM
Jun 16, 2026 09:05AM
Jun 16, 2026 09:05AM
May 20, 2026 04:20PM
May 20, 2026 04:20PM BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia
May 18, 2026 09:05AM
May 18, 2026 09:05AM
May 4, 2026 04:05PM
May 4, 2026 05:54AM
May 2, 2026 03:30PM
Apr 27, 2026 08:44AM
Apr 27, 2026 08:44AM BioMarin Completes Acquisition of Amicus Therapeutics
Apr 21, 2026 04:24PM
Apr 21, 2026 04:23PM
Mar 12, 2026 09:05AM
Mar 12, 2026 09:05AM
Mar 2, 2026 04:34PM
Feb 27, 2026 08:00PM
Feb 25, 2026 06:38AM BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $55 at H.C. Wainwright
Feb 23, 2026 04:05PM
Feb 18, 2026 05:31PM
Feb 12, 2026 07:41AM
Dec 19, 2025 07:45AM
Dec 19, 2025 07:45AM
Oct 29, 2025 09:01AM
Oct 29, 2025 09:00AM FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria
Oct 28, 2025 06:41AM
Oct 27, 2025 04:03PM
Sep 8, 2025 09:00AM
Sep 6, 2025 11:05AM
Sep 6, 2025 11:05AM
Aug 30, 2025 04:00PM
Aug 4, 2025 04:02PM BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS
Jul 15, 2025 06:15AM
Jun 25, 2025 10:03AM
Jun 24, 2025 09:02AM
Jun 24, 2025 09:00AM
Jun 5, 2025 12:44PM
May 12, 2025 09:06AM
May 12, 2025 09:05AM BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings
May 1, 2025 04:05PM
Apr 10, 2025 05:32AM
Apr 2, 2025 09:06AM
Apr 2, 2025 09:00AM
Mar 20, 2025 09:00AM
Mar 11, 2025 07:05AM
Feb 19, 2025 04:05PM BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance
Nov 30, 2024 04:00AM

326,126 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All